Lakefront Biotherapeutics NV (LKFT) is in Healthcare, Biotechnology, based in Belgium, listed on NasdaqGS. Market cap 1.93B USD. 52-week range 25.68 to 36.24 USD. Trailing P/E 2.8. Data as of 2026-10-09.
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured ...